克罗恩病患者血清7α-羟基-4-胆甾烯-3-酮浓度与胆汁酸性腹泻相关
研究比较26例克罗恩病(CD)伴回肠切除(IR)、21例CD不伴IR和37例溃疡性结肠炎(UC)患者的血清C4与FGF19浓度,发现CD伴IR者C4中位浓度显著高于UC;C4≥48.3 ng/mL诊断胆汁酸吸收不良所致腹泻的AUROC为0.94,C4可能成为识别该类腹泻的生物标志物。
要点
- CD伴IR伴回肠炎者血清C4中位浓度100.0 ng/mL,显著高于UC的11.8 ng/mL(P<.0001)。
- C4≥48.3 ng/mL诊断胆汁酸吸收不良所致腹泻的灵敏度90.9%、特异度84.4%、AUROC 0.94。
- C4浓度与每日排便次数相关(r=0.41,P=.004),与FGF19浓度负相关(r=-0.72,P<.0001)。
核心结论
- CD伴IR患者血清C4浓度显著高于UC患者;C4>48.3 ng/mL可识别可能由胆汁酸吸收不良所致的腹泻,AUROC为0.94。
- 血清胆汁酸前体升高可识别腹泻且FGF19<60 pg/mL的患者,C4浓度与每日液体排便次数相关并与FGF19浓度负相关。
- C4可能成为识别胆汁酸吸收不良所致腹泻患者的生物标志物。
研究设计与样本
- 收集26例CD伴IR、21例CD不伴IR和37例UC患者的人口学数据、血清样本、腹泻(>3次液体排便/天)信息及临床、内镜和组织学评分。
- 比较各组间血清C4与成纤维细胞生长因子19(FGF19)浓度,并用受试者工作特征曲线下面积(AUROC)分析确定诊断胆汁酸吸收不良所致腹泻(定义为腹泻且血清FGF19<60 pg/mL)的最佳C4截断值。
主要发现
- UC患者血清C4中位浓度11.8 ng/mL;CD伴IR伴内镜证实的回肠炎者中位浓度100.0 ng/mL(与UC比较P<.0001),CD伴IR不伴回肠炎者中位浓度51.6 ng/mL(与UC比较P<.001)。
- CD不伴IR患者C4中位浓度与UC无显著差异(P=.71),无论有无回肠炎(P=.34);组织学证实内镜所见时结果与仅用内镜所见分析相似。
- 活动期UC患者腹泻比例更高(72.0% vs 非活动期UC 0%;P<.001),但C4中位浓度与非活动期UC无显著差异(12.1 ng/mL vs 9.7 ng/mL;P=.3)。
- C4截断值≥48.3 ng/mL识别胆汁酸吸收不良所致腹泻的灵敏度90.9%、特异度84.4%、AUROC 0.94;高于该截断值者胆汁酸吸收不良比例50.0%,高于低于该截断值者的1.8%(P<.001)。
- 仅分析腹泻患者时,C4截断值48.3 ng/mL识别FGF19<60 pg/mL者的灵敏度91%、特异度95.5%(AUROC 0.99);高于该截断值者83.3%血清FGF19<60 pg/mL,低于该阈值者4.5%(P<.0001)。
关键数值与推荐
- 胆汁酸吸收不良所致腹泻定义为腹泻且血清FGF19<60 pg/mL。
- C4截断值≥48.3 ng/mL诊断胆汁酸吸收不良所致腹泻:灵敏度90.9%、特异度84.4%、AUROC 0.94。
- 仅腹泻患者中C4截断值48.3 ng/mL识别FGF19<60 pg/mL:灵敏度91%、特异度95.5%、AUROC 0.99。
临床怎么用
- 原文结论认为C4可能成为识别胆汁酸吸收不良所致腹泻患者的生物标志物,未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with Crohn's disease (CD) often have bile acid diarrhea (BAD), due to bile acid malabsorption following ileal resection (IR). Bile acid malabsorption increases production of 7α-hydroxy-4-cholesten-3-one (C4), a bile acid precursor. We investigated relationships between serum concentrations of C4 and BAD in patients with CD. METHODS: We collected demographic data, serum samples, and information on the presence of diarrhea (>3 liquid bowel movements/day), as well as clinical, endoscopic, and histologic scores from 26 patients with CD and IR, 21 patients with CD without IR, and 37 patients with ulcerative colitis (UC). We compared serum concentrations of C4 and fibroblast growth factor 19 (FGF19) between groups. We performed area under the receiver operating characteristic curve (AUROC) analysis to identify the optimal cutoff C4 concentrations for the diagnosis of diarrhea attributable to bile acid malabsorption (BAD), defined as diarrhea and a serum concentration of FGF19 <60 pg/mL. RESULTS: Patients with UC had a median serum C4 concentration of 11.8 ng/mL, whereas patients with CD and IR with ileitis (documented endoscopically) had a median concentration of 100.0 ng/mL (P compared to UC < .0001) and patients with CD and IR without ileitis had a median concentration of 51.6 ng/mL (P compared to UC < .001). Patients with CD without IR did not have a significantly higher median concentration of C4 than patients with UC (P = .71), regardless of ileitis (P = .34). When endoscopic findings were confirmed histologically, similar results were found to analyses using endoscopic findings alone. A higher proportion of patients with active UC had diarrhea (72.0% vs 0 patients with inactive UC; P < .001), but their median concentrations of C4 did not differ significantly from that of patients with inactive UC (12.1 ng/mL vs 9.7 ng/mL; P = .3). A cutoff concentration of C4 of 48.3 ng/mL or greater identified patients with diarrhea attributable to bile acid malabsorption with 90.9% sensitivity, 84.4% specificity, and an AUROC 0.94. A significantly higher proportion of patients with concentrations of C4 above this cutoff had BAD (50.0%) than below this cutoff (1.8%) (P < .001). When we analyzed only patients with diarrhea, a C4 cutoff of 48.3 ng/mL identified those with low FGF19 concentrations (<60 pg/mL) with 91% sensitivity and 95.5% specificity (AUROC, 0.99). Above this cutoff, 83.3% of patients had a serum concentration of FGF19 <60 pg/mL compared to 4.5% below this threshold (P < .0001). C4 concentrations correlated with the number of daily bowel movements (r = 0.41; P = .004) and correlated inversely with FGF19 concentrations (r = -0.72; P<.0001). CONCLUSION: We observed significantly increased serum concentrations of C4 in patients with CD with IR, compared to patients with UC. A cutoff concentration of C4 above 48.3 ng/mL identifies patients with diarrhea likely attributable to bile acid malabsorption (BAD) with an AUROC value of 0.94. Increased serum levels of bile acid precursors identify patients with diarrhea and a low serum concentration of FGF19, and concentrations of C4 correlate with daily liquid bowel movements and correlate inversely with FGF19 concentrations. C4 may be a biomarker to identify patients with diarrhea attributable to bile acid malabsorption.
引用
- Battat R, Duijvestein M, Vande Casteele N, et al. Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2018. PMID: 30448597. doi:10.1016/j.cgh.2018.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。